A promising new therapy for Duchenne muscular dystrophy (DMD) is heading to the FDA's advisory committee. The agency has scheduled a July 29, 2026, review of Capricor Therapeutics' deramiocel, a cell therapy that showed meaningful improvements in upper limb function and heart health in clinical trials. A final FDA decision is expected by August 22, 2026.
The FDA's Cellular, Tissue, and Gene Therapies Advisory Committee is set to review Capricor Therapeutics' biologics license application (BLA) for deramiocel on July 29, 2026 — with a final decision expected by August 22. The review comes after the FDA rescinded an earlier complete response letter (CRL) that had flagged deficiencies in efficacy evidence and manufacturing controls, following the submission of new phase 3 data.
Deramiocel is an allogeneic cardiosphere-derived cell therapy that works not by restoring dystrophin, but by releasing extracellular vesicles that reduce inflammation and fibrosis. In the pivotal phase 3 HOPE-3 trial (n=105), the therapy slowed disease progression by 54% on upper limb function scores and reduced the decline in heart function by 91% on cardiac MRI — both statistically significant results. Earlier phase 2 HOPE-2 data also showed a 36.2% improvement in upper limb function over placebo.
By the Numbers:
Why it matters: DMD is a devastating, progressive disease with no cure, and heart and respiratory complications are leading causes of death. Deramiocel could become the first cell therapy approved for DMD, offering a new treatment avenue for nonambulatory patients who have few options beyond supportive care.
